|
|
|
Article Cited by others RESEARCH ARTICLE
Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
Davis Joseph A, Singh Shuchita, Sethi Sachin, Roy Subhasis, Mittra Shivani, Rayasam Geetavani, Bansal Vinay, Sattigeri Jitendra, Ray Abhijit
Year : 2010| Volume: 42| Issue : 4 | Page no: 229-233 | This article has been cited by | | 1 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) |
|
| | Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya | | | Cardiovascular Diabetology. 2012; 11(1): 92 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Compare clinical efficacy between vildagliptin 100 mg and sitagliptin 100 mg in inadequate patients with sitagliptin 50 mg |
|
| | Kuribayashi, N. | | | Therapeutic Research. 2012; 33(5): 703-710 | | | [Pubmed] [Google Scholar] | | | 3 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
| | P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan | | | Biomedicine & Preventive Nutrition. 2011; 1(4): 268 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
| | Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E.B., Dunning, B.E., Foley, J.E. | | | Diabetes, Obesity and Metabolism. 2011; 13(9): 775-783 | | | [Pubmed] [Google Scholar] | | | 5 |
Clinical experience of a selective dipeptidyl peptidase IV inhibitor, vildagliptin |
|
| | Tomioka, Y. | | | Therapeutic Research. 2011; 32(6): 841-849 | | | [Pubmed] [Google Scholar] | | | 6 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
| | Greene, R.J., Tu, H., Gibbs, J.P., Greg Slatter, J. | | | Xenobiotica. 2011; 41(11): 945-957 | | | [Pubmed] [Google Scholar] | | | 7 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
| | Bansal, P., Paul, P., Shankar, G., Munjal, D., Nayak, P.G., Priyadarsini, K.I., Unnikrishnan, M.K. | | | Biomedicine and Preventive Nutrition. 2011; 1(4): 268-272 | | | [Pubmed] [Google Scholar] | | | 8 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
| | B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley | | | Diabetes, Obesity and Metabolism. 2011; 13(9): 775 | | | [Pubmed] [Google Scholar] [DOI] | | | 9 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
| | Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter | | | Xenobiotica. 2011; 41(11): 945 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
